Adenocarcinoma de próstata. Modelo clínico predictivo de afectación de vesícula seminal / Prostate adenocarcinoma. Predictive clinical model of seminal vesicle involvement
Arch. esp. urol. (Ed. impr.)
; 66(6): 576-583, jul.-ago. 2013. tab
Article
in Spanish
| IBECS
| ID: ibc-114160
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
OBJETIVOS:
Se pretende diseñar utilizando los datos clínicos un modelo predictivo de afectación de vesícula seminal.MÉTODOS:
Se estudian 1.128 pacientes con adenocarcinoma clínicamente localizado tratados mediante prostatectomía radical (127 son pT3b). Se identifican (regresión logística) las variables clínicas relacionadas con pT3b. Con las variables del estudio multivariado se diseña un modelo de riesgo de afectación de vesícula seminal.RESULTADOS:
Factores relacionados con afectación de vesícula seminal En estudio univariado las variables influyentes son Gleason 7 (OR2); Gleason 8-10 (OR4,5); T2 (OR2,6); afectación bilateral en biopsia (OR3,1); PSA 10-20 ng/ml (OR3,3); PSA >20 ng/ml (OR9,5). En el estudio multivariado son influyentes Gleason 7 (OR1,56); Gleason 8-10 (OR 3,4); T2 (OR1,9); PSA 10-20 ng/ml (OR3,1) y PSA >20 ng/ml (OR8,8). MODELO PREDICTIVO mediante regresión logística multivariante se valora el peso de cada variable y se da un valor entre 1 y 4. Gleason 2-6, T1; PSA<10 ng/ml valor 1; Gleason 7; T2 y PSA 10-20 ng/ml valor 2; Gleason 8-10 y PSA >20 ng/ml valor 4. Cada paciente tiene un marcador que oscila entre 3 y 10. Se diseñan 5 grupos con riesgos significativamente diferentes (p<0,05 en todos los casos) Grupo 1 (3 puntos)(OR1)(riesgo 2,4%; IC95% 0,7%-4,3%). Grupo 2 (4 puntos) (OR2,7)(riesgo 6,5%; IC95% 5%-7,9%). Grupo 3 (5-6 puntos)(OR7,1) (riesgo15%; IC95% 11%-19%). Grupo 4 (7-8 puntos)(OR33,4)(riesgo 45,5%; IC95% 30%-59%). Grupo 5 (9-10 puntos)(OR57,3)(riesgo 58,8%; IC95% 35%-82%).CONCLUSIÓN:
El modelo clínico permite una aproximación precisa al riesgo de afectación de vesículas seminales (AU)ABSTRACT
OBJECTIVES:
Our aim is to design a predictive model of seminal vesicle involvement. using clinical data.METHODS:
We studied 1128 patients with clinically localized adenocarcinoma treated by radical prostatectomy (127 were pT3b). We identified (logistic regression) clinical variables related with pT3b. With the multivariate study influential variables a seminal vesicle involvement risk model is designed.RESULTS:
Seminal vesicle involvement related factors In univariate study the influential variables are Gleason 7 (OR2);Gleason 8-10 (OR4.5); T2 (OR2.6); bilateral involvement in biopsy (OR3.1); PSA 10-20 ng/ml (OR3.3); PSA >20 ng/ml (OR9.5). In the multivariate study are influential Gleason 7 (OR 1.56); Gleason 8-10 (OR 3.4); T2 (OR1.9); PSA 10-20 ng/ml (OR3.1) and PSA >20 ng/ml (OR8.8). Predictive model using multivariate logistic regression the weight of each variable is valued and a value between 1 and 4 is given. Gleason 2-6, T1; PSA<10 ng/ml value 1; Gleason 7; T2 y PSA 10-20 ng/ml value 2; Gleason 8-10 and PSA >20 ng/ml value 4. Each patient has a marker that fluctuates between 3 and 10. 5 Groups are designed with significantly different risks (p<0.05 in all cases) Group 1 (3 points) (OR1)(risk 2.4%; 95%IC 0.7%-4.3%) Group 2 (4 points) (OR2.7)(risk 6.5%; 95%IC 5%-7.9%) Group 3 (5-6 points) (OR7.1)(risk15%; 95%IC 11%-19%) Group 4 (7-8 points) (OR33.4)(risk 45.5%; 95%IC 30%-59%) Group 5 (9-10 points) (OR57.3)(risk 58.8%; 95%IC 35%-82%).CONCLUSION:
The clinical model allows an accurate approximation to the seminal vesicles involvement risk (AU)
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Prostatic Neoplasms
/
Seminal Vesicles
/
Adenocarcinoma
/
Risk Factors
Type of study:
Etiology study
/
Prognostic study
/
Risk factors
Limits:
Humans
/
Male
Language:
Spanish
Journal:
Arch. esp. urol. (Ed. impr.)
Year:
2013
Document type:
Article
Institution/Affiliation country:
Clínica Universidad de Navarra/España